

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2617)

VOLUNTARY ANNOUNCEMENT
INCLUSION OF THE COMPANY AS A CONSTITUENT OF THE HANG
SENG INDEX SERIES

This announcement is made by TransThera Sciences (Nanjing), Inc. (the “**Company**”, together with its subsidiaries collectively referred to as the “**Group**”) on a voluntary basis, the purpose of which is to inform the shareholders and potential investors of the Company of the latest development of the Company.

The board of directors (the “**Board**”) of the Company is pleased to announce that, pursuant to the quarterly review results of the Hang Seng Index Series published by Hang Seng Indexes Company Limited on February 13, 2026, the Company has been selected and will be included as a constituent of the Hang Seng Index Series, including but not limited to the following, with effect from March 9, 2026:

1. Hang Seng Composite LargeCap & MidCap Index;
2. Hang Seng Large-Mid Cap (Investable) Index;
3. Hang Seng Composite MidCap Index;
4. Hang Seng Stock Connect Hong Kong Index;
5. Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index;
6. Hang Seng Large-Mid Cap Equal Weighted Factor Mix (QVLM) Index;
7. Hang Seng Large-Mid Cap Low Volatility Comprehensive Index;
8. Hang Seng Large-Mid Cap Momentum Comprehensive Index;
9. Hang Seng Large-Mid Cap Quality Comprehensive Index;
10. Hang Seng Large-Mid Cap Risk Parity Factor Mix (QVLM) Index;
11. Hang Seng Large-Mid Cap Low Size Comprehensive Index;
12. Hang Seng Large-Mid Cap Value Comprehensive Index;

13. Hang Seng Large-Mid Cap Dividend Yield Comprehensive Index;
14. Hang Seng SCHK Mainland China Companies Index; and
15. Hang Seng Stock Connect Biotech 50 Index.

Meanwhile, the Company has been deleted from the Hang Seng Composite SmallCap Index, with effect from March 9, 2026.

The Board believes that the Company's inclusion in the aforementioned indices reflects growing recognition from investors.

By Order of the Board
TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, March 9, 2026

As at the date of this announcement, the Board comprises (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin and Dr. Yi Hua as non-executive directors; and (iii) Mr. Li Shu Pai, Ms. Chui Hoi Yam and Ms. Zheng Zhelan as independent non-executive directors.